Zheng Quan Zhi Xing·2025-08-21 16:58Group 1 - The board of directors of Kanglong Chemical held its 15th meeting on August 21, 2025, to discuss various proposals, including the approval of the 2025 semi-annual report and the decision not to distribute cash dividends for the year [1][2] - The board approved an additional investment of $10.5 million in the joint venture PharmaGend Global Medical Services Pte. Ltd. in Singapore, which is part of a $30 million financing round for infrastructure and operational expenses [3][4] - The board also approved adjustments to the stock incentive plans for 2021, 2022, and 2023, including changes to the grant prices due to capital adjustments [6][7] Group 2 - The company announced that the conditions for the fourth vesting period of the 2021 stock incentive plan have been met, allowing for the vesting of 329,331 shares, which will remain under lock-up until January 26, 2026 [8] - Similarly, the conditions for the third vesting period of the 2022 stock incentive plan have been met, allowing for the vesting of 681,766 shares, which will also remain under lock-up until January 27, 2026 [9] - The board approved the cancellation of unvested shares from the stock incentive plans for 2021, 2022, and 2023 due to the departure of certain incentive recipients [10][11] Group 3 - The company revised and added several governance policies to reduce compliance risks and meet EcoVadis and client evaluation requirements, including updates to training policies and sustainable procurement management [12]